Form 4 for NMRA Neumora Therapeutics, Inc.
Accepted 2024-10-18 00:00:00 ET · period of report 2024-10-17 · accession 0001610717-24-000511 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2024-10-18 | 2024-10-17+ | NMRA | Fust Matthew K | Dir | M - OptEx | $5.83 | +21.8K | 34.1K | +176% | +$127.0K |
| DMT | 2024-10-18 | 2024-10-17+ | NMRA | Fust Matthew K | Dir | S - Sale+OE | $17.02 | -21.8K | 20.1K | -52% | -$370.9K |
| DMT | 2024-10-18 | 2024-10-17+ | NMRA | Fust Matthew K | Dir | M - OptEx | $0.00 | -21.8K | 6,205 | -78% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-10-18 | M | A | 6,205 | $8.79 | 26,305 | D | — | — | |
| 2 | Common | Common Stock | 2024-10-17 | M | A | 3,783 | $8.32 | 23,883 | D | — | — | |
| 3 | Common | Common Stock | 2024-10-17 | M | A | 1,800 | $8.79 | 25,683 | D | — | — | |
| 4 | Common | Common Stock | 2024-10-17 | M | A | 2,156 | $2.52 | 27,839 | D | — | — | |
| 5 | Common | Common Stock | 2024-10-17 | S | D | 7,739 | $17.01 | 20,100 | D | — | — | (F2) This transaction was executed in multiple trades in prices ranging from $17.00 to $17.045, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| 6 | Common | Common Stock | 2024-10-18 | M | A | 7,844 | $2.52 | 34,149 | D | — | — | |
| 7 | Common | Common Stock | 2024-10-18 | S | D | 14,049 | $17.03 | 20,100 | D | — | — | (F3) This transaction was executed in multiple trades in prices ranging from $17.00 to $17.15, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| 8 | Derivative | Stock Option (Right to Buy) | 2024-10-18 | M | D | 7,844 | $0.00 | 85,586 | D | $2.52 · — to 2031-04-22 | 7,844 Common Stock | (F4) The shares subject to the option are fully vested and exercisable. |
| 9 | Derivative | Stock Option (Right to Buy) | 2024-10-18 | M | D | 6,205 | $0.00 | 0 | D | $8.79 · — to 2030-09-07 | 6,205 Common Stock | (F4) The shares subject to the option are fully vested and exercisable. |
| 10 | Derivative | Stock Option (Right to Buy) | 2024-10-17 | M | D | 2,156 | $0.00 | 93,430 | D | $2.52 · — to 2031-04-22 | 2,156 Common Stock | (F4) The shares subject to the option are fully vested and exercisable. |
| 11 | Derivative | Stock Option (Right to Buy) | 2024-10-17 | M | D | 3,783 | $0.00 | 0 | D | $8.32 · — to 2030-09-07 | 3,783 Common Stock | (F4) The shares subject to the option are fully vested and exercisable. |
| 12 | Derivative | Stock Option (Right to Buy) | 2024-10-17 | M | D | 1,800 | $0.00 | 6,205 | D | $8.79 · — to 2030-09-07 | 1,800 Common Stock | (F4) The shares subject to the option are fully vested and exercisable. |